Due to BCL-XL could block BAX translocation [33], imatinib decreased BCL-XL expression and further reactivated BAX (6A7) expression, leading to apoptosis in Ph+ B-ALL cells (Fig. 4D). The gene discussed is BCL2L1; the disease is acute lymphoblastic leukemia.